作者
Steven M. Horwitz,Owen A. O’Connor,Barbara Pro,Tim Illidge,Michelle A. Fanale,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo‐Domènech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Anne Lennard,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su‐Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Swaminathan P. Iyer,Pier Luigi Zinzani,Zhaowei Hua,Meredith Little,Shangbang Rao,Joseph Woolery,Thomas Manley,Lorenz Trümper,David M. Aboulafia,Ranjana H. Advani,Önder Alpdoğan,Kiyoshi Ando,Luca Arcaini,Luca Baldini,Naresh Bellam,Nancy L. Bartlett,David Belada,Dina Ben Yehuda,Fabio Benedetti,Peter Borchman,Dominique Bordessoule,Pauline Brice,Javier Briones,Dolores Caballero,Angelo Michele Carella,Hung Chang,June Weon Cheong,Seok‐Goo Cho,Ilseung Choi,Sylvain Choquet,Andrei Coliţă,Angela Giovanna Congui,Francesco d’Amore,Nam H. Dang,Kelly Davison,Sophie de Guibert,Peter de Nully Brown,Vincent Delwail,Judit Demeter,Francesco Di Raimondo,Young Rok,Eva Domingo,Michael G. Douvas,Martin Dreyling,Thomas Ernst,Michelle A. Fanale,Keith Fay,Tatyana Feldman,Silvia Ferrero,Ian W. Flinn,Andres Forero‐Torres,Christopher P. Fox,Jonathan W. Friedberg,Noriko Fukuhara,José A. García‐Marco,Jorge Gayoso Cruz,José Codina,Rémy Gressin,Andrew Grigg,Ronit Gurion,Jacob Haaber Christensen,Corinne Haïoun,Roman Hájek,Mathias Hänel,Kiyohiko Hatake,Robert Hensen,Netanel A. Horowitz,Steven M. Horwitz,Andreas Hüttmann,Árpád Illés,Tim Illidge,Kenichi Ishizawa,Miguel Islas‐Ohlmayer,Eric D. Jacobsen,Murali Janakiram,Wojciech Jurczak,Mark Kaminski,Koji Kato,Won Seog Kim,Ilya Kirgner,Swaminathan P. Iyer,Ching‐Yuan Kuo,Mihaela Lazaroiu,Katell Le Dû,Jong Seok Lee,Steven Le Gouill,Anne Lennard,Paul La Rosée,Itai Levi,Brian K. Link,Hervé Maisonneuve,Dai Maruyama,Jiří Mayer,John M. McCarty,Pam McKay,Yosuke Minami,Heidi Móciková,Enrica Morra,Franck Morschhauser,Javier Muñoz,Hirokazu Nagai,Owen A. O’Connor,Stephen Opat,Ruth Pettengell,Antonio Pezzutto,Michael Pfreundschuh,Andrzej Pluta,Pierluigi Porcu,Barbara Pro,Hang Quach,Alessandro Rambaldi,William Renwick,Ruben Reyes,Antonia Rodríguez Izquierdo,Giuseppe Rossi,Jia Ruan,Chiara Rusconi,Gilles Salles,Armando Santoro,Jose E. Sarriera,Kerry J. Savage,Hirohiko Shibayama,Andrei R. Shustov,Cheolwon Suh,Anna Sureda,Mitsune Tanimoto,Masafumi Taniwaki,Hervé Tilly,Kensei Tobinai,Marek Trněný,Lorenz Trümper,Norifumi Tsukamoto,Kunihiro Tsukasaki,Umberto Vitolo,Jan Walewski,Eckhart Weidmann,Martin Wilhelm,Mathias Witzens‐Harig,Abdulraheem Yacoub,Kazuhito Yamamoto,Su‐Peng Yeh,Sung-Soo Yoon,Sam Yuen,Hwan‐Jung Yun,Jasmine Zain,Pier Luigi Zinzani
摘要
Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.ECHELON-2 is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults from 132 sites in 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. Randomisation was stratified by histological subtype according to local pathology assessment and by international prognostic index score. All patients received cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 on day 1 of each cycle intravenously and prednisone 100 mg once daily on days 1 to 5 of each cycle orally, followed by either brentuximab vedotin 1·8 mg/kg and a placebo form of vincristine intravenously (A+CHP group) or vincristine 1·4 mg/m2 and a placebo form of brentuximab vedotin intravenously (CHOP group) on day 1 of each cycle. The primary endpoint, progression-free survival according to blinded independent central review, was analysed by intent-to-treat. This trial is registered with ClinicalTrials.gov, number NCT01777152.Between Jan 24, 2013, and Nov 7, 2016, 601 patients assessed for eligibility, of whom 452 patients were enrolled and 226 were randomly assigned to both the A+CHP group and the CHOP group. Median progression-free survival was 48·2 months (95% CI 35·2-not evaluable) in the A+CHP group and 20·8 months (12·7-47·6) in the CHOP group (hazard ratio 0·71 [95% CI 0·54-0·93], p=0·0110). Adverse events, including incidence and severity of febrile neutropenia (41 [18%] patients in the A+CHP group and 33 [15%] in the CHOP group) and peripheral neuropathy (117 [52%] in the A+CHP group and 124 [55%] in the CHOP group), were similar between groups. Fatal adverse events occurred in seven (3%) patients in the A+CHP group and nine (4%) in the CHOP group.Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.Seattle Genetics Inc, Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Institutes of Health National Cancer Institute Cancer Center.